Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

TCON

TRACON Pharmaceuticals Inc

Dec 05 • 04:00PM ET

0.2070

Dollar change +0.0040
Percentage change 1.97	%

Healthcare • Biotechnology • USA • NASD

Stock Detail • Compare Perf. • Options Chain • Save to Portfolio • Create Alert

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-0.58	Insider Own	15.21%	Shs Outstand	31.14M	Perf Week	14.36%
Market Cap	6.45M	Forward P/E	-	EPS next Y	-0.50	Insider Trans	0.00%	Shs Float	26.41M	Perf Month	39.77%
Income	-11.02M	PEG	-	EPS next Q	-0.10	Inst Own	29.64%	Short Float / Ratio	7.62% / 0.48	Perf Quarter	-19.27%
Sales	9.00M	P/S	0.72	EPS this Y	59.95%	Inst Trans	-0.06%	Short Interest	2.01M	Perf Half Y	-66.07%
Book/sh	-0.10	P/B	-	EPS next Y	10.18%	ROA	-75.82%	Target Price	4.00	Perf Year	-86.20%
Cash/sh	0.25	P/C	0.83	EPS next 5Y	-	ROE	-1277.01%	52W Range	0.13 - 2.19	Perf YTD	-86.11%
Dividend	-	P/FCF	-	EPS past 5Y	34.33%	ROI	-	52W High	-90.55%	Beta	1.00
Dividend %	-	Quick Ratio	0.71	Sales past 5Y	-53.15%	Gross Margin	99.83%	52W Low	64.94%	ATR	0.03
Employees	18	Current Ratio	0.71	Sales Q/Q	-	Oper. Margin	-145.97%	RSI (14)	56.70	Volatility	15.02% 16.96%
Optionable	Yes	Debt/Eq	-	EPS Q/Q	197.43%	Profit Margin	-122.49%	Rel Volume	0.57	Prev Close	0.20
Shortable	Yes	LT Debt/Eq	-	Earnings	Nov 09 AMC	Payout	-	Avg Volume	4.22M	Price	0.21
Recom	1.67	SMA20	12.34%	SMA50	18.97%	SMA200	-68.00%	Volume	2,398,086	Change	1.97%

Date	Action	Analyst	Rating Change	Price Target Change
Apr-16-21	Upgrade	BTIG Research	Neutral → Buy	$14
Feb-10-21	Initiated	Maxim Group	Buy	$24
Dec-23-19	Reiterated	H.C. Wainwright	Buy	$15 → $18
Mar-01-19	Reiterated	Needham	Buy	$7
Jun-13-17	Reiterated	Stifel	Buy	$14 → $6
Dec-21-16	Initiated	Jefferies	Buy	$10
Feb-01-16	Resumed	Oppenheimer	Outperform
Jul-29-15	Initiated	ROTH Capital	Buy	$18
Mar-02-15	Reiterated	Stifel	Buy	$16 → $20
Mar-02-15	Reiterated	Oppenheimer	Outperform	$22 → $26
Feb-24-15	Initiated	Stifel	Buy	$16
Feb-24-15	Initiated	Oppenheimer	Outperform	$22

Show Previous Ratings

Nov-21-23 07:55AM	Why Is Tracon Pharmaceuticals (TCON) Stock Up 19% Today? (InvestorPlace) +25.07%
07:32AM	Todays Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday (InvestorPlace)
Nov-20-23 08:00AM	TRACON Pharmaceuticals Announces License of Product Development Platform for $3.0 Million Upfront Payment (GlobeNewswire)
Nov-13-23 09:29AM	Why Is Tracon Pharmaceuticals (TCON) Stock Down 22% Today? (InvestorPlace) -7.08%
Nov-12-23 08:47AM	TRACON Pharmaceuticals, Inc. (NASDAQ:TCON) Q3 2023 Earnings Call Transcript (Insider Monkey)
07:45AM	Loading…
Nov-10-23 07:45AM	Why Is Tracon Pharmaceuticals (TCON) Stock Up 130% Today? (InvestorPlace) +43.94%
Nov-09-23 04:58PM	Tracon: Q3 Earnings Snapshot (Associated Press Finance)
04:02PM	TRACON Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Corporate Update (GlobeNewswire)
Oct-31-23 04:02PM	TRACON to Report Third Quarter 2023 Financial Results and Provide Corporate Update on November 9, 2023 (GlobeNewswire) +11.35%
Sep-18-23 08:00AM	TRACON Pharmaceuticals Announces ENVASARC Phase 2 Pivotal Trial Exceeded Futility Threshold at Final Interim Analysis and Will Continue as Planned (GlobeNewswire)
Sep-05-23 04:02PM	TRACON Pharmaceuticals Announces Participation at Upcoming Investor Conferences (GlobeNewswire)
Aug-25-23 07:20AM	7 F-Rated Biotech Stocks You Shouldnt Touch With a 10-Foot Pole (InvestorPlace)
Aug-15-23 08:43AM	Q2 2023 TRACON Pharmaceuticals Inc Earnings Call (Thomson Reuters StreetEvents) -6.95%
Aug-14-23 07:00PM	Tracon: Q2 Earnings Snapshot (Associated Press Finance) -9.66%
04:02PM	TRACON Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Corporate Update (GlobeNewswire)
04:05PM	Loading…
Aug-02-23 04:05PM	TRACON to Report Second Quarter 2023 Financial Results and Provide Corporate Update on August 14, 2023 (GlobeNewswire) +14.06%
Jul-11-23 08:00AM	TRACON Pharmaceuticals Announces Collection of Arbitration Award from I-Mab Biopharma (GlobeNewswire) +5.52%
Jun-20-23 08:00AM	TRACON Pharmaceuticals Announces Positive Results Based on Ongoing Double-Digit Objective Response Rate for Single Agent Envafolimab in the ENVASARC Phase 2 Pivotal Trial (GlobeNewswire)
Jun-16-23 08:00AM	TRACON Pharmaceuticals to Present at the Maxim Group Healthcare Virtual Conference (GlobeNewswire)
Jun-15-23 08:00AM	TRACON Pharmaceuticals Announces Enforcement Action to Collect Binding Arbitration Award from I-Mab Biopharma (GlobeNewswire) -5.91%
Jun-02-23 08:00AM	TRACON Pharmaceuticals to Present at the Jefferies Healthcare Conference (GlobeNewswire) +7.93%
May-30-23 08:00AM	TRACON Pharmaceuticals Announces Poster Presentations for Envafolimab and TRC102 at the 2023 ASCO Annual Meeting (GlobeNewswire)
May-11-23 11:24AM	Q1 2023 TRACON Pharmaceuticals Inc Earnings Call (Thomson Reuters StreetEvents) -6.14%
May-10-23 04:38PM	Tracon: Q1 Earnings Snapshot (AP Finance)
04:02PM	TRACON Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Corporate Update (GlobeNewswire)
May-03-23 04:02PM	TRACON to Report First Quarter 2023 Financial Results and Provide Corporate Update on May 10, 2023 (GlobeNewswire) +5.19%
Apr-25-23 07:41AM	TRACON Pharmaceuticals Announces Arbitration Award in Dispute with I-Mab (GlobeNewswire) -46.63%
Apr-06-23 08:30AM	Runway Growth Finance Corp. Provides First Quarter 2023 Portfolio Update (GlobeNewswire) +6.19%
Mar-14-23 12:00PM	Tracon (TCON) Moves to Buy: Rationale Behind the Upgrade (Zacks) +6.16%
Mar-10-23 02:26AM	TRACON Pharmaceuticals, Inc. (NASDAQ:TCON) Q4 2022 Earnings Call Transcript (Insider Monkey) +8.33%
05:49AM	Loading…
Mar-09-23 05:49AM	Q4 2022 TRACON Pharmaceuticals Inc Earnings Call (Thomson Reuters StreetEvents)
Mar-08-23 04:02PM	TRACON Pharmaceuticals Reports Fourth Quarter and Year-End 2022 Financial Results and Provides Corporate Update (GlobeNewswire) -8.00%
Feb-28-23 04:02PM	TRACON to Report Fourth Quarter and Year-End 2022 Financial Results and Provide Corporate Update on March 8, 2023 (GlobeNewswire)
Jan-20-23 06:55AM	Daily Vickers Top Buyers & Sellers for 01/20/2023 (Argus Research)
Jan-10-23 08:30AM	Runway Growth Finance Corp. Provides Fourth Quarter 2022 Portfolio Update (GlobeNewswire)
Dec-27-22 08:00AM	TRACON Pharmaceuticals Announces up to $30M Non-Recourse Non-Dilutive Financing Related to Arbitration Award Decision Expected in Q1 2023 (GlobeNewswire) +10.34%
Dec-14-22 11:29AM	TRACON Touts Encouraging Objective Response Rates For Mid-Stage Cancer Study (Benzinga)
08:00AM	TRACON Pharmaceuticals Announces Positive Results Based on Double-Digit Objective Response Rate in Each Cohort from the Ongoing ENVASARC Phase 2 Pivotal Trial (GlobeNewswire)
Nov-21-22 08:00AM	TRACON Pharmaceuticals Announces Dosing of First Patient in Phase 1/2 Trial of YH001 in Combination with Envafolimab and Doxorubicin in Front Line Sarcoma (GlobeNewswire)
Nov-14-22 04:02PM	TRACON Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Corporate Update (GlobeNewswire) +9.03%
Oct-31-22 08:00AM	TRACON to Report Third Quarter 2022 Financial Results and Provide Corporate Update on November 14, 2022 (GlobeNewswire)
Oct-06-22 08:30AM	Runway Growth Finance Corp. Provides Third Quarter 2022 Portfolio Update (GlobeNewswire) +6.63%
08:00AM	TRACON Pharmaceuticals Announces Results of Independent Data Monitoring Committee Review of 12 Week Safety Data from ENVASARC Phase 2 Pivotal Trial - Trial to Proceed as Planned (GlobeNewswire)
Sep-14-22 08:00AM	TRACON Pharmaceuticals Announces Fast Track Designation by the FDA for Envafolimab for the Treatment of the Soft Tissue Sarcoma Subtypes of UPS and MFS (GlobeNewswire)
Sep-07-22 08:00AM	TRACON Pharmaceuticals Announces Participation at Upcoming Investor Conferences (GlobeNewswire)
Sep-06-22 08:00AM	TRACON Pharmaceuticals Announces $35 Million Non-Dilutive Debt Financing with Runway Growth Capital (GlobeNewswire) -5.53%
Aug-29-22 08:00PM	US FDA Approval of IND for CTLA-4 Antibody YH001 for the Treatment of Front-line Sarcoma Patients in Combination with Envafolimab (Business Wire)
11:45AM	TRACON Secures FDA Nod For Early-Stage Study In Soft-Tissue Cancer (Benzinga)
08:00AM	TRACON Pharmaceuticals Announces Approval of IND for CTLA-4 Antibody YH001 for the Treatment of Front-line Sarcoma Patients in Combination with Envafolimab (GlobeNewswire)
Aug-10-22 04:02PM	TRACON Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Corporate Update (GlobeNewswire) +10.11%
08:00AM	TRACON Pharmaceuticals Announces Results of Independent Data Monitoring Committee Review of Safety Data from ENVASARC Pivotal Trial (GlobeNewswire)
Aug-08-22 08:00AM	TRACON Pharmaceuticals Announces Submission of IND Application for CTLA-4 Antibody YH001 for the Treatment of Front-line Sarcoma Patients in Combination with Envafolimab (GlobeNewswire)
Jul-27-22 08:05AM	TRACON to Report Second Quarter 2022 Financial Results and Provide Corporate Update on August 10, 2022 (GlobeNewswire) +6.32%
Jul-26-22 08:05AM	TRACON Pharmaceuticals Announces Dosing of 36th Patient in ENVASARC Pivotal Trial Triggering Initial IDMC Efficacy Review Expected in the Fourth Quarter (GlobeNewswire)
Jun-02-22 08:05AM	TRACON Pharmaceuticals to Present at the Jefferies Healthcare Conference (GlobeNewswire)
May-16-22 08:05AM	TRACON Pharmaceuticals to Present at the H.C. Wainwright Global Investment Conference (GlobeNewswire) +15.57%
May-11-22 04:02PM	TRACON Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Corporate Update (GlobeNewswire)
May-04-22 08:05AM	TRACON to Report First Quarter 2022 Financial Results and Corporate Update on May 11, 2022 (GlobeNewswire)
Apr-19-22 08:05AM	TRACON Pharmaceuticals Announces Amended ENVASARC Protocol Approved and Open at all 30 Clinical Sites in the U.S. and U.K. (GlobeNewswire)
Apr-08-22 05:02PM	Recession Fears are Creating a Golden Opportunity for Biotech Stocks (InvestorPlace)
Mar-23-22 08:05AM	TRACON Pharmaceuticals to Present at the Maxim Group 2022 Virtual Growth Conference (GlobeNewswire) +9.16%
Mar-15-22 04:02PM	TRACON Pharmaceuticals Reports Fourth Quarter and Year-End 2021 Financial Results and Provides Corporate Update (GlobeNewswire)
Mar-11-22 08:05AM	TRACON Pharmaceuticals to Present at the Oppenheimer 32nd Annual Healthcare Conference (GlobeNewswire) -6.85%
Mar-10-22 08:05AM	TRACON Pharmaceuticals Announces FDA Approval of Amended ENVASARC Protocol (GlobeNewswire) +18.22%
Mar-04-22 08:05AM	TRACON to Report Fourth Quarter and Full Year 2021 Financial Results and Corporate Update on March 15, 2022 (GlobeNewswire)
Feb-02-22 08:05AM	TRACON Pharmaceuticals Announces Initiation of Randomized Phase 2 Trial of TRC102 in Lung Cancer Sponsored by the National Cancer Institute (GlobeNewswire)
Jan-05-22 08:05AM	TRACON Pharmaceuticals to Present at the H.C. Wainwright BIOCONNECT Virtual Conference (GlobeNewswire) -9.25%
Dec-27-21 08:00AM	TRACON Pharmaceuticals Announces Positive Results from the Independent Data Monitoring Committee Review of Interim Safety and Efficacy Data from the Ongoing ENVASARC Pivotal Trial (GlobeNewswire) -20.16%
Nov-29-21 08:05AM	TRACON Pharmaceuticals Reports Regulatory Approval of Envafolimab in China (GlobeNewswire)
Nov-11-21 08:05AM	TRACON Pharmaceuticals to Present at the Jefferies London Virtual Healthcare Conference (GlobeNewswire)
Nov-03-21 04:02PM	TRACON Pharmaceuticals Reports Third Quarter 2021 Financial Results and Provides Corporate Update (GlobeNewswire)
Oct-27-21 08:05AM	TRACON to Report Third Quarter 2021 Financial Results and Company Highlights on November 3, 2021 (GlobeNewswire)
Oct-13-21 08:00AM	TRACON Pharmaceuticals Announces Appointment of Carol Lam to its Board of Directors (GlobeNewswire)
Oct-11-21 01:27PM	TRACON Pharma, Eucure Join Forces To Develop CTLA-4 Antibody For Oncology Indications (Benzinga) +7.96%
08:00AM	TRACON Pharmaceuticals and Eucure Biopharma, a Subsidiary of Biocytogen, Announce Partnership for Development of Clinical Stage CTLA-4 Antibody YH001 (GlobeNewswire)
Sep-13-21 08:05AM	TRACON Pharmaceuticals to Present at the Oppenheimer Fall Healthcare Life Sciences and MedTech Summit (GlobeNewswire)
Sep-07-21 08:05AM	TRACON Pharmaceuticals to Present at the H.C. Wainwright 23rd Annual Global Investment Conference (GlobeNewswire)
07:29AM	TRACON Pharmaceuticals on the Fast Track for Sarcoma Injection Treatments (Benzinga)
Sep-02-21 08:05AM	TRACON Pharmaceuticals to Present at the Wells Fargo Virtual Healthcare Conference (GlobeNewswire) +6.04%
Aug-11-21 04:02PM	TRACON Pharmaceuticals Reports Second Quarter 2021 Financial Results and Provides Corporate Update (GlobeNewswire)
Aug-09-21 08:05AM	TRACON Pharmaceuticals Announces Results of Second Independent Data Monitoring Committee Review of Safety Data from ENVASARC Pivotal Trial (GlobeNewswire)
Aug-03-21 08:05AM	TRACON Pharmaceuticals to Present at the BTIG Virtual Biotechnology Conference (GlobeNewswire) -10.05%
Jul-28-21 08:05AM	TRACON to Report Second Quarter 2021 Financial Results and Company Highlights on August 11, 2021 (GlobeNewswire)
Jul-21-21 10:30PM	TRACON Pharmaceuticals Increases Previously Announced Bought Deal Offering of Common Stock to $15.0 Million (GlobeNewswire)
05:27PM	TRACON Pharmaceuticals Announces $10 Million Bought Deal Offering of Common Stock (GlobeNewswire)
Jul-20-21 08:05AM	TRACON Pharmaceuticals Announces Appointment of Brenda Marczi, PharmD, as Senior Vice President, Regulatory Affairs, and Granting of Inducement Award (GlobeNewswire) +5.10%
Jun-30-21 08:05AM	TRACON Pharmaceuticals Announces Appointment of Ya Huang as Executive Director of Statistical Programming and Granting of Inducement Award (GlobeNewswire)
Jun-29-21 08:05AM	TRACON Pharmaceuticals Announces Orphan Drug Designation for Envafolimab in Soft Tissue Sarcoma (GlobeNewswire)
Jun-28-21 01:04PM	Is TRACON Pharmaceuticals Inc (TCON) A Good Stock To Buy? (Insider Monkey)
Jun-18-21 10:08AM	3 Strong Buy Stocks Under $10 With Over 100% Upside Potential (TipRanks) +10.17%
Jun-04-21 09:01AM	TRACON Pharmaceuticals Presents Data from a Phase 1 Study of Uliledlimab (TJ004309) and Tecentriq® (Atezolizumab) at the American Society of Clinical Oncology Virtual Annual Meeting (GlobeNewswire)
Jun-01-21 08:05AM	TRACON Pharmaceuticals Announces Results of Independent Data Monitoring Committee Review of Safety Data from ENVASARC Pivotal Trial (GlobeNewswire)
May-25-21 08:05AM	TRACON Pharmaceuticals to Present at the Jefferies Virtual Healthcare Conference (GlobeNewswire)
May-20-21 08:05AM	TRACON Pharmaceuticals Announces Poster Presentations at the 2021 ASCO Virtual Annual Meeting (GlobeNewswire)
May-05-21 04:03PM	TRACON Pharmaceuticals Reports First Quarter 2021 Financial Results and Provides Corporate Update (GlobeNewswire) -7.20%
02:45PM	TRACON Pharmaceuticals, Inc. to Host Earnings Call (ACCESSWIRE)
08:25AM	SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating TRACON Pharmaceuticals, Inc. for Potential Breaches of Fiduciary Duty By Its Board of Directors (ACCESSWIRE)
May-03-21 08:05AM	TRACON Pharmaceuticals Announces Appointment of Dongliang Zhuang, Ph.D. as Vice President of Statistics and Biometrics (GlobeNewswire)
Apr-28-21 08:05AM	TRACON to Report First Quarter 2021 Financial Results and Company Highlights on May 5, 2021 (GlobeNewswire)
Apr-26-21 08:00AM	SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating TRACON Pharmaceuticals, Inc. for Potential Breaches of Fiduciary Duty By Its Board of Directors (PR Newswire) +5.31%

TRACON Pharmaceuticals, Inc. engages in the development and commercialization of targeted therapies for cancer, and ophthalmic and fibrotic diseases. Its products include TRC105, an anti-endoglin antibody for the treatment of solid tumor types, TRC205 created for the treatment of fibrotic diseases, and TRC102, a small molecule that is in clinical development made for lung cancer and glioblastoma. The company was founded in October 2004 and is headquartered in San Diego, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
THEUER CHARLES	President and CEO	Apr 27	Buy	0.75	47,000	35,250	399,417	Apr 28 06:00 AM
THEUER CHARLES	President and CEO	Apr 26	Buy	0.66	3,999	2,639	352,417	Apr 28 06:00 AM
Opaleye Management Inc.	10% Owner	Mar 09	Buy	1.38	174,508	240,821	4,324,508	Mar 13 04:05 PM
THEUER CHARLES	President and CEO	Mar 01	Buy	1.52	4,800	7,296	344,918	Mar 02 06:24 AM
THEUER CHARLES	President and CEO	Feb 28	Buy	1.52	200	304	340,118	Mar 02 06:24 AM
THEUER CHARLES	President and CEO	Jan 18	Buy	1.62	6,800	11,016	339,918	Jan 19 06:05 AM
Brown Scott B.	Chief Financial Officer	Dec 29	Buy	1.49	3,500	5,215	21,628	Jan 03 06:00 AM
LARUE WILLIAM R	Director	Dec 21	Sale	1.26	120	151	7,763	Jan 19 06:00 AM
Opaleye Management Inc.	10% Owner	Dec 14	Buy	1.25	167,500	209,876	4,150,000	Dec 16 05:03 PM
THEUER CHARLES	President and CEO	Dec 14	Buy	1.29	23,000	29,755	333,118	Dec 15 06:00 AM
Opaleye Management Inc.	10% Owner	Dec 06	Sale	1.44	1,539	2,216	4,010,000	Dec 08 06:49 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

TCON

TRACON Pharmaceuticals Inc

Upgrade your FINVIZ experience